Forodesine: Interim Phase II data

Interim data from an ongoing, open-label, U.S. and Australian Phase II trial in 25 patients who had failed >=1 prior treatment regimen showed that 200 mg twice-daily oral forodesine produced 3 partial responses. BioCryst previously reported that 200 mg once-daily forodesine substantially reduced malignant lymphocytes in 5 of 13 evaluable patients and subsequently amended the study to test the 200 mg twice-daily dose (see BioCentury, Jan. 5, 2009). ...